CSL CEO Paul Perreault Earns 2018 Most Admired CEOs Recognition from the Philadelphia Business Journal

Perreault leads the fifth largest biotechnology company in the world with more than 22,000 employees providing lifesaving medicines to patients in more than 60 countries.

KING OF PRUSSIA, Pa. – December 6, 2018 – Paul Perreault, CEO and Managing Director of CSL Limited, is one of the Philadelphia Business Journal’s Most Admired CEOs for 2018, recognizing his patient-focused leadership of the world’s fifth largest biotechnology company.

“In choosing the winners of the Most Admired CEO Awards, the editorial board of the Philadelphia Business Journal looks for evidence of true leadership – at the company, organization or firm and in the community,” said Craig Ey, Editor-in-Chief, Philadelphia Business Journal. “We considered accomplishments, leadership traits and community service in selecting this year’s honorees.”

Since taking the helm of CSL in 2013, Perreault has led the company on an unprecedented journey – enhancing a dynamic portfolio of lifesaving medicines, including those that treat hemophilia, hereditary angioedema and immune deficiencies, as well as vaccines to prevent influenza. Through its two businesses: CSL Behring, a global leader in providing lifesaving biotherapies for people stricken with rare and serious diseases, with operational headquarters in King of Prussia; and Seqirus, the world’s second largest influenza vaccine provider, CSL medicines now reach patients in more than 60 countries.

“I have the best job in the world,” Perreault said. “For more than a century, the people of CSL have delivered on our promise to develop and provide innovative medicines and programs for people with serious medical conditions. It is a privilege to lead more than 22,000 ‘Chief Patient Officers’ – employees who are dedicated to working every day as if someone’s life depends on it, because it does.”

During Perreault’s tenure as CEO, CSL’s global employment has nearly doubled and the company’s sustainable growth is expected to continue. In 2017, Forbes magazine named CSL among the Top 50 employers in the world for the first time and, in 2018, Thomson Reuters ranked CSL as one of the top 100 companies in its global Diversity and Inclusion Index. 

Company revenue for its fiscal year 2018 was $7.9 billion, up 11 percent at constant currency from the prior year. Additionally – CSL’s share price has more than tripled since Perreault assumed the role of CEO.

For more information about Paul Perreault, please click here.

About CSL Behring

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease and neurological disorders. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 22,000 people, and delivers its lifesaving therapies to people in more than 60 countries. For inspiring stories about the promise of biotechnology, visit Vita at CSLBehring.com/Vita and follow us on Twitter.com/CSLBehring.

###

Media Contact:
Greg Healy
Office: +1 610-878-4841
Mobile: +1 610-906-4564
Email: Greg.Healy@CSLBehring.com